Article

J&J hit with $1.2 Billion Penalty in Drug Case

An Arkansas judge slapped Johnson & Johnson and a subsidiary with more than $1.2 billion in penalties on Wednesday for deceptive marketing of the antipsychotic drug Risperdal.

The ruling marks the latest legal headache for J&J over the drug. Johnson & Johnson has faced lawsuits in a total of 11 states in connection with Risperdal.

Read the full story: http://hcp.lv/IJ94hi

Source: CNN Money

Related Videos
Fulling and Cournoyer
Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network
Tiara Green, MSEd
Panagis Galiatsatos, MD, MHS, an expert on bronchiectasis
Panagis Galiatsatos, MD, MHS, an expert on bronchiectasis
Jason Porter, MD, an expert on lung cancer
Jason Porter, MD, an expert on lung cancer
Joseph Mikhael, MD, an expert on multiple myeloma
A panel of 3 experts on multiple sclerosis
A panel of 3 experts on multiple sclerosis
Related Content
soft tissue sarcoma | Image Credit: Dr_Microbe-stock.adobe.com
July 26th 2024

Immunotherapy for Angiosarcoma: Promising Results for Scalp and Face Tumors

Sabrina Serani
The Alliance AO91902 trial investigated whether adding immunotherapy to chemotherapy would improve outcomes for patients with advanced angiosarcoma.
Managed Care Cast logo
July 25th 2024

Dr Jason Spangler on Enhancing Equity in Health Technology Assessment

Brooke McCormick
On this episode of Managed Care Cast, we're talking with Jason Spangler, MD, MPH, CEO of the Center for Innovation and Value Research on equity challenges within health technology assessment.
SMA spinal muscular atrophy | Image Credit: © Rochu_2008 - stock.adobe.com
July 26th 2024

Potential Biomarkers Predict Disease Severity and Treatment Response in SMA

Kyle Munz
Results from a single-center, observational, prospective study suggested that inflammatory markers could predict disease severity and treatment efficacy for patients with spinal muscular atrophy (SMA).
Managed Care Cast: Frameworks for Advancing Health Equity
July 23rd 2024

Frameworks for Advancing Health Equity: Health Equity by Design

Giuliana Grossi
Melissa Clarke, MD, CMQ, the chief health equity officer at Elevance Health, explains "Health Equity by Design" and how Elevance Health is committed to ensuring a personalized and intentional approach for all its members.
FDA approval stamp. | Image Credit: Surendra - stock.adobe.com
July 26th 2024

FDA Approves Deuruxolitinib for Alopecia Areata

Cameron Santoro
The FDA has approved deuruxolitinib, an oral medication developed by Sun Pharma, as the first-line treatment for adults with moderate to severe alopecia areata.
In the Press
July 26th 2024

AJMC® in the Press, July 26, 2024

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo